Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study

European Urology

Volumn 53, Issue 4, 2008, Pages 777-784

  Rosario, Derek J ^a   Lane, J Athene ^b   Metcalfe, Chris ^b   Catto, James W ^a   Dedman, Daniel ^d   Donovan, Jenny L ^b   Neal, David E ^c   Hamdy, Freddie C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Prostate Cancer; Prostate Specific Antigen; RCT; Screening; Sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

AGED; BIOPSY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; ROC CURVE;

EID: 39549117783     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.11.064     Document Type: Article

References (22)

1. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower [see comment]. JAMA 294 (2005) 66-70
2. McLernon D.J., Donnan P.T., Gray M., Weller D., and Sullivan F. Receiver operating characteristics of the prostate specific antigen test in an unselected population. J Med Screen 13 (2006) 102-107
3. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
4. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
5. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements [see comment]. JAMA 277 (1997) 1452-1455
6. Schroder F.H., Roobol-Bouts M., Vis A.N., van der K.T., and Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 57 (2001) 83-90
7. Bruun L., Becker C., Hugosson J., Lilja H., and Christensson A. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 65 (2005) 216-221
8. Soletormos G., Semjonow A., Sibley P.E., et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice [review] [71 refs]. Clin Chem 51 (2005) 1342-1351
9. Donovan J.L., Mills N., Smith M., et al. Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 325 (2002) 766-770
10. Eskicorapci S.Y., Baydar D.E., Akbal C., et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 45 (2004) 444-449
11. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839-843
12. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 (2007) 928-935
13. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
14. Eastham J.A., Riedel E., Scardino P.T., et al., Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695-2700
15. Singh R., Cahill D., Popert R., and O'Brien T.S. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy [see comment]. BJU Intl 92 (2003) 932-935
16. Boddy J.L., Pike D.J., Al-Hayek S., Shaida N., and Malone P.R. An elevated PSA, which normalizes, does not exclude the presence of prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 349-352
17. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
18. Roddam A.W., Rimmer J., Nickerson C., and Ward A.M. NHS Prostate Cancer Risk Management Program. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 43 (2006) 1-48
19. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
20. Oesterling J.E., Jacobsen S.J., and Cooner W.H. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 153 (1995) 1160-1163
21. Steyerberg E.W., Roobol M.J., Kattan M.W., van der Kwast T.H., De Koning H.J., and Schroder F.H. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177 (2007) 107-112
22. Nam R.K., Toi A., Klotz L.H., et al. Assessing individual risk for prostate cancer. J Clin Oncol 25 (2007) 3582-3588